Tesaro Inc. (NASDAQ:TSRO) SVP Martin H. Jr. Huber sold 408 shares of the business’s stock in a transaction dated Thursday, September 22nd. The shares were sold at an average price of $108.12, for a total value of $44,112.96. Following the completion of the sale, the senior vice president now directly owns 1,250 shares of the company’s stock, valued at $135,150. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Tesaro Inc. (NASDAQ:TSRO) opened at 108.59 on Friday. The firm’s market cap is $5.58 billion. The firm’s 50-day moving average price is $94.16 and its 200 day moving average price is $64.76. Tesaro Inc. has a 52-week low of $29.51 and a 52-week high of $110.48.
Tesaro (NASDAQ:TSRO) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.71) by $0.43. The company had revenue of $36.60 million for the quarter, compared to analysts’ expectations of $4.98 million. Tesaro had a negative return on equity of 205.63% and a negative net margin of 783.97%. During the same quarter in the previous year, the company posted ($1.51) earnings per share. On average, equities analysts anticipate that Tesaro Inc. will post ($7.36) earnings per share for the current year.
Several analysts have recently weighed in on TSRO shares. Bank of America Corp. started coverage on Tesaro in a report on Tuesday, August 30th. They issued a “neutral” rating and a $97.00 target price for the company. FBR & Co boosted their target price on Tesaro from $65.00 to $93.00 and gave the company an “outperform” rating in a report on Wednesday, June 29th. Citigroup Inc. boosted their target price on Tesaro from $90.00 to $120.00 and gave the company a “buy” rating in a report on Monday, August 8th. Mizuho boosted their target price on Tesaro from $67.00 to $94.00 and gave the company a “buy” rating in a report on Tuesday, July 5th. Finally, Robert W. Baird started coverage on Tesaro in a report on Monday, July 18th. They issued an “outperform” rating and a $105.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $94.40.
Several large investors have recently added to or reduced their stakes in the stock. KCG Holdings Inc. acquired a new stake in Tesaro during the second quarter worth $228,000. Quantitative Systematic Strategies LLC acquired a new stake in Tesaro during the second quarter worth $240,000. Parametrica Management Ltd acquired a new stake in Tesaro during the first quarter worth $251,000. Bluestein R H & Co. acquired a new stake in Tesaro during the second quarter worth $252,000. Finally, Neuberger Berman Group LLC acquired a new stake in Tesaro during the second quarter worth $256,000. 88.81% of the stock is currently owned by institutional investors.
Tesaro Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
Receive News & Ratings for Tesaro Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro Inc. and related companies with MarketBeat.com's FREE daily email newsletter.